Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Envision Sciences
Adelaide, South Australia, Australiaenvisionsciences.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Envision Sciences has developed a panel of highly sensitive and specific prostate cancer IHC biomarkers, now commercialized through Quest Diagnostics in the US. Their technology aims to improve accuracy in diagnosis and grading of prostate cancers. Additional programs are under development for colorectal, ovarian cancers, and melanoma.[1][3][6]
- Therapeutic areas
- Oncology
- Modalities
- BiomarkersDiagnostic assays (IHC, blood tests)
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
University of South Australia (collaborative research partner)[1][3]Quest Diagnostics (commercialization partner for US market)[6]
Beyond the preview
Go deeper on Envision Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Envision Sciences.